Ligand Pharmaceuticals Incorporated
LGND
$294.60
$5.782.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 463.49% | -129.80% | -61.81% | 2,319.50% | 111.42% |
| Total Depreciation and Amortization | -0.01% | 0.02% | -0.67% | -2.97% | -2.83% |
| Total Amortization of Deferred Charges | 1.64% | 22.68% | 12.85% | 72.44% | -24.05% |
| Total Other Non-Cash Items | -157.89% | 367.86% | 83.05% | -1,374.34% | -36.49% |
| Change in Net Operating Assets | -218.96% | -36.65% | 187.51% | -72.01% | -19.41% |
| Cash from Operations | -50.67% | 6.05% | 250.76% | -17.15% | 162.09% |
| Capital Expenditure | 88.60% | -2,433.33% | 40.00% | 92.99% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 441.21% | -840.25% | 97.17% | -3,281.13% | -304.64% |
| Cash from Investing | 440.36% | -421.14% | 94.88% | -3,213.44% | -317.96% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -2,797,000.00% | 0.00% | 99.99% | -1,617,842.86% | 0.00% |
| Issuance of Common Stock | 12.37% | -17.68% | -63.88% | 212.44% | 95.14% |
| Repurchase of Common Stock | -177.70% | -6,216.86% | 97.74% | -10,395.86% | 98.37% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 188,050.00% | 91.90% | -101.18% | 658.22% | 9,829.58% |
| Cash from Financing | 3,966.37% | -269.66% | -97.97% | 2,631.88% | 415.88% |
| Foreign Exchange rate Adjustments | 188.64% | 92.54% | -47.50% | -117.45% | 116.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 202.85% | -3,411.54% |
| Net Change in Cash | 1,590.16% | -268.30% | -50.42% | 264.36% | 180.93% |